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10.4 10.6%, respectively. Procedural success was 99%. Coronary dissections occurred
in 14.7%, and bailout BMS was required in 13 patients (11.9%). Mean follow-up was 7.5
months; follow-up rate was 99%. Cumulative MACE at follow-up was 8.7%, with 1%
all-cause death, 1% myocardial infarction, 6.9% overall target vessel revascularization; of
which 2.9% were target lesion revascularizations, and no vessel thrombosis. Angiographic
follow-up of a subset of patients (n26) demonstrated late luminal loss of 0.30  0.36
mm and 0.33  0.37 mm for the in-DCB and in-segment analyses, respectively.
Conclusions: The Valentines II trial demonstrated the safety and efficacy of second-
generation DIOR DCB as adjunct to POBA in an all-comer population with de novo
coronary lesions. This approach achieved high procedural success with acceptable rates of
bailout stenting and low MACE rates at mid-term follow-up, and offers an attractive
alternative for revascularization of patients who are not good candidates.
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Background: In-stent restenosis (ISR) is a persistent problem limiting the long-term
success of percutaneous coronary intervention. Recent studies have demonstrated safety
and efficacy of drug-eluting balloon (DEB) angioplasty for the treatment of coronary ISR.
The cost-effectiveness of this practice is unknown.
Methods: A Markov state-transition decision analytic model was used to assess the
comparative cost-effectiveness of two common treatment strategies for bare-metal stent
(BMS)-ISR: stenting with paclitaxel-eluting DES (drug-eluting stent) versus paclitaxel-
eluting balloon angioplasty (SeQuent Please). The model accounted for varying proce-
dural efficacy rates, complication rates, and cost estimates. Data on procedural outcomes
associated with both treatment strategies were derived from the literature, and the cost
analysis was conducted from a German health care payer perspective. Effectiveness was
expressed as life-years gained. Cost-effectiveness was calculated by dividing the differ-
ence in mean costs by the difference in effectiveness.
Results: In the base-case analysis, initial procedure costs amounted to $4,497.27 for DEB
angioplasty and to $4,128.81 for DES implantation. Over a 12-month time horizon, the
DEB strategy was found to be less costly ($5,154.47 versus $6,619.98) and slightly more
effective in terms of life expectancy (0.983 versus 0.976 years) than the DES strategy.
Extensive sensitivity analyses indicated that, in comparison with DES implantation, the
cost advantage of the DEB strategy was robust to clinically plausible variations in the
values of key model input parameters. The variables with the greatest impact on base case
Results were the duration of dual antiplatelet therapy after DEB angioplasty, the use of
generic clopidogrel, and variations in the costs associated with the DEB device.
Conclusions: DEB angioplasty is a cost-effective treatment option for coronary BMS-
ISR. The higher initial costs of DEB are more than offset by later cost savings,
predominantly as a result of reduced medication costs. DEB angioplasty can be regarded
as one of the rare innovative medical interventions that are cost-saving at equal or even
increased effectiveness.
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Background: In spite of all the technical developments that have taken place in coronary
artery disease treatment, small diffusely calcified vessels are yet challenging. Rotational
atherectomy (ROTA) has an undisputed role in the debulking of severely calcified
arteries, followed by drug eluting stent implantation for best long term Results. There are
cases, however, where delivering a stent proves to be impossible or inappropriate. In such
patients (pts) drug eluting balloons (DEB) could provide a therapeutic option. AIMS: We
present the preliminary Results of the experience of 3 cardiovascular intervention centers
on the use of ROTA followed by DEB (ROTA-DEB).
Methods: All data on pts submitted to rotablation is prospectively collected in a database.
Pts in which ROTA-DEB was performed, accepted to angiographic follow-up (Fup-
angio) after a minimum of 6 months. Lesions were assessed by QCA at the time of
intervention. Post ROTA-DEB and at Fup, QCA was done after intra coronary
administration of nitrates in the same plane as basal QCA and along the length of the
DEB.
Results: In our multicenter registry, from 1/6/2009 to 31/5/2012, 204 consecutive pts
were submitted to ROTA, of which 21 (10.3%) were followed by DEB (32 balloons
(average size: 2.45 (2-4) mm x 21.66 (15-30) mm). Most common indications for DEB
were: distal vessel  2 mm (59.4%) and difficulties in stent delivering (25%). Angio-
graphic success was achieved in all but 2 lesions(91%): 1 final QCA  50% and 1
required bail-out stenting. All pts showed a marked improvement in clinical status. At 12
months, freedom from major cardiac adverse events was 90%. Fup-angio(refused by 3
pts)was obtained at a median of 424  254 days. QCA analysis showed an average late
luminal loss (LLL) of -6% (-62% to 	75%). LLL  50% was present in 1 pt.
Conclusions: Although these are still small numbers, Results seem very promising,
considering the complexity of the lesions. For very severe, diffusely calcified coronary
artery disease, ROTA-DEB constitutes a good therapeutic option when a stent cannot be
implanted.
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Background: The efficacy of paclitaxel-eluting balloon (PEB) for in-stent restenotic
lesions is proven; however, its efficacy for recurrences after drug-eluting stent (DES)
implantation for in-stent restenosis (stent in stent lesions) remains unclear. The aim of this
study was to investigate the efficacy of PEB in patients with recurrences after DES
implantation for in-stent restenosis.
Methods: From November 2004 to December 2011, 159 consecutive lesions who
underwent revascularization for recurrences after DESs for in-stent restenosis were
enrolled in this study [77 treated with PEB and 82 treated with conventional balloon
angioplasty (BA)]. Follow-up angiogram was obtained 6 months after the procedure. We
compared characteristics of patients and lesions between the two groups (PEB group vs
BA group).
Results: No significant differences were observed in clinical characteristics between the
two groups. Angiographic characteristics before the procedure were similar between the
two groups (Reference diameter: 3.07  0.56 mm vs 3.07  0.55 mm, p  0.9; Lesion
length: 18.0  15.0 mm vs 15.0  11.7 mm, p  0.1; Minimal lumen diameter: 0.85 
0.53 mm vs 0.95  0.58 mm, p  0.3). Acute gain was also similar between the two
groups (1.33  0.69 mm vs 1.26  0.68mm, p  0.5). At the 6-month angiographic
follow-up (follow-up rate: 94%), the incidence of recurrent restenosis (29.2% vs 59.7%,
p  0.0003) and target lesion revascularization (23.6% vs 40.3%, p  0.036) was
significantly lower in the PEB group than in the BA group. Late lumen loss was
significantly lower in the PEB group than in the BA group (0.46  0.63 mm vs 0.82 
0.73 mm, p  0.0017).
Conclusions: In patients with recurrent restenosis after DES implantation for in-stent
restenosis(stent in stent lesions), PEB provided much better clinical, angiographic
outcomes than conventional BA.
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Background: In comparison to the original PACCOCATH formulation, second gener-
ation PCB have improved coating uniformity and decreased drug content variability by
modifying coating Methods and processes. In this study, we intended to evaluate the
differences in biological efficacy and vascular healing response of 2nd generation PCB in
comparison to a 1st generation balloons technologies containing identical coating
formulation and drug concentration.
Methods: A total of 18 Ilio-femoral arterial segments of 8 FHS were included in the
study. At baseline overstretch balloon injury followed by self-expanding BMS implan-
tation was performed. Two weeks following initial injury, all stents were randomized to
either a 2nd gen. PCB (n6, Cotavance V2, Medrad), 1st gen. PCB (n6, PACCO-
CATH, Medrad) or POBA (n6, control group). Imaging evaluation (QVA, IVUS) was
conducted in all animals at baseline, treatment time (2 weeks) and 28 days following
treatment. At termination, stented segments were harvested for histopathological evalu-
ation.
Results: At last follow up angiographic %DS was significantly reduced in both
generations of PCBs when compared to controls (2nd Gen PCB: 11.511.1% vs. 1st Gen
PCB: 21.911.0% vs. POBA: 46.510.9%; p0.01). These findings were confirmed by
histopathological analysis (see table) displaying an 35% reduction of %AS and
neointimal thickness in both PCB groups. Vessel healing defined as fibrin deposition,
neointimal maturity and medial cell loss scores was significantly improved in 2nd Gen PCB
when compared to 1st Gen PCB. Endothelialization was completed in all three groups.
TUESDAY, OCTOBER 23, 8:00 AM–10:00 AMwww.jacc.tctabstracts2012.com
JACC Vol 60/17/Suppl B | October 22–26, 2012 | TCT Abstracts/POSTER/Drug-Coated Balloon B171
P
O
ST
E
R
S
2nd Gen PCB 1st Gen PCB POBA p
Area of
Stenosis (%)
50.5 54.8 18.1% 78.2 9.8% 0.01
Neointimal
Thickness (mm)
0.85 0.2 0.86 0.4 1.35 0.2 0.01
Fibrin deposition
(0-3)
0.5 [0.3-0.7] 2.4 [2-3] 0.1# 0.01
Neointimal
maturity (0-3)
3# 1.3 [1-1.8] 3# 0.01
Medial cell loss
(0-3)
3# 1.7 [1-1.8] 3# 0.01
Endothelialization
(0-3)
3# 2.5 [2-2.6] 3# 0.01
p0.05 vs. POBA. #p0.05 vs. 1st gen PCB
Conclusions: Second generation PCB achieved similar degree of neointimal inhibition
compared to 1st generation PCB technologies. However, they displayed a more favorable
vascular healing profile.
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Background: Juvenile domestic swine have been extensively used to test safety of
various antirestenotic therapies in peripheral arteries but it generally fails to provide
insights into efficacy. We investigated the potential of different combinations of balloon
or stent injury	treatment models in familial hypercholesterolemic (FH) swine to predict
the antirestenotic efficacy of drug-coated balloons.
Methods: Iliofemoral arteries of 32 FH swine were subjected to (1) denudation by a
Fogarty catheter immediately followed by DCB or Control (uncoated PTCA balloon)
treatment (De Novo Denudation	No Stent), (2) balloon overstretch and stent placement
immediately followed by the same DCB or Control treatment (De Novo
Overstretch	Stent), or (3) balloon overstretch and stent placement followed by the same
DCB or Control treatment 14-21 days later (In-Stent Restenosis). In all models, the net
neointimal proliferation was evaluated 28 days post-treatment by endovascular imaging
(IVUS or OCT).
Results: As expected, the neointimal response was much more robust in the De Novo
Overstretch	Stent than in the De Novo Denudation	No Stent model, but both De Novo
FH swine models failed to show the difference between DCB and Control. In contrast, 2
separate studies employing the In-Stent Restenosis model on the basis of FH swine,
demonstrated reduction of average stenosis by 50% by DCB in comparison to Control
(TABLE).
Conclusions: The peripheral in-stent restenosis model, in which neointimal proliferation
was induced by stent placement in iliofemoral arteries of FH swine and dilated 2-3 weeks
later by DCB or Control uncoated balloon, reliably differentiated the antirestenotic effect
of DCB from the Control effect in peripheral arteries. In contrast, either De Novo model
(of contemporaneous injury	treatment) developed in FH swine was not successful in that
regard.
Model
Imaging
Modality
Average Percent Area Stenosis
P value
Control
(Uncoated Balloon)
Drug-Coated
Balloon
De Novo
Denudation	No
Stent (n16)
IVUS 17.3 3.9% 19.0 4.7% 0.24
De Novo
Overstretch	Stent
(n11)
OCT 56.5 14.5% 43.8 13.4% 0.17
In-Stent Restenosis
(n16)
IVUS 58.3 11.6% 25.5 8.6% 0.001
In-Stent Restenosis
(n16)
OCT 47.0 13.0% 27.3 8.7% 0.003
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for The Treatment of In-Stent Restenosis (ISR)
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Background: In recent studies, efficacy of drug-eluting balloon (DEB) angioplasty for
the treatment of coronary in-stent restenosis (ISR) was demonstrated. However there is
few data regarding efficacy and safety of DEB compared to drug-eluting stent (DES) in
treating ISR.
Methods: Initially we tried to evaluate the efficacy and safety of DEB for ISR. Instead
we compared the DEB data to other DES data prospectively obtained in our institution in
the same period. In this prospective registry from 2009 to 2010, 107 patients with ISR,
treated with a DEB (Paclitaxel-coated) (61 patients, 65 lesions) and DES (resolute
zotarolimus-eluting) (46 patients, 50 lesions) were included. Nine month angiographic
and 1 year clinical follow-up were completed for all patients. Dual antiplatelet agents were
administered for both groups at least 9 months. Safety endpoints were cardiac death,
myocardial infarction or stent thrombosis, and efficacy endpoints were more than 50% of
ISR and repeated target lesion revascularization (TLR) during follow-up.
Results: Baseline clinical and angiographic data did not significantly differ between two
groups. After 9 months TLR and ISR rates were significantly lower in DES group vs.
DEB group with 6.0% vs. 21.5% respectively (p0.02). Moreover, adverse cardiac events
(composite of cardiac death, myocardial infarction) occurred in DEB group (n2) while
there was no myocardial infarction in DES group.
Conclusions: Substituting DEB for DES as a repeated revascularization tool might not
be feasible in the maintenance of vascular patency in treating ISR.
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Background: In recent years, drug coated balloons have emerged as treatment option for
PCI. The present registry aims to evaluate the safety and efficacy of the Pantera Lux
Paclitaxel Coated Balloon in a real world setting.
Methods: Between April 2010 and April 2011, 1’064 patients were enrolled at 62 sites
in 12 countries. Clinical follow-up was performed at 1, 6 and 12 months. The primary
endpoint was MACE, a composite of all death, non-fatal MI and clinically driven TVR,
at 6 months. Secondary endpoints include MACE at 1 and 12 months. All reported MACE
were adjudicated by an independent clinical events committee.
Results: Seven hundred ninety-four men (74.6%) and 270 female (25.4%) with a mean
age of 66.5 10.7 yrs have been enrolled. Two hundred nineteen patients (20.6%)
presented with congestive heart failure, 362 patients (34.1%) were diabetics and 51.8%
(n551) had a history of previous MI. The majority of patients presented with stable
angina (n528, 49.6%) followed by unstable angina (n350, 32.9%). A total of 1’137
lesions were treated, mainly located in LAD (n436, 38.3%) and RCA (n410, 36.1%).
The mean reference vessel diameter was 2.8 mm and the mean target lesion length was
15.7 mm. Nine hundred ninety-seven lesions (87.7%) were in-stent restenotic (ISR)
lesions. Thereof 540 lesions were in a BMS (54.2%) and 448 lesions in a DES (44.9%).
The majority of ISR lesions were diffuse (n475, 49.0%, Mehran class II) or focal
(n316, 32.6%, Mehran class I). Follow-up compliance at 6 month follow up is 93.9%.
The MACE rate (hierarchical) at 6 months is 8.7% including 29 all death (2.9%, 19
cardiac death [1.9%]), 13 non-fatal MI (1.3%) and 44 clinically driven TVR (4.4%). In 32
cases (3.2%) a target lesion revascularization was needed. Twelve months MACE data
will be presented.
Conclusions: Treatment with the Pantera Lux Paclitaxel Coating Balloon showed
excellent acute and mid term performance in patients with mainly ISR lesions.
Efficacy and safety are demonstrated by low revascularization rates and low
non-fatal MI rate.
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